Seeking Alpha

Ascendiant Capital Markets initiates coverage on StemCells (STEM +1.7% to $2.44) with a "Buy"...

Ascendiant Capital Markets initiates coverage on StemCells (STEM +1.7% to $2.44) with a "Buy" recommendation and a price target of $2.60. "We believe that StemCells is an intriguing speculative small cap investment story," Ascendiant writes. "The Company is breaking new ground in its development of novel stem cell therapies."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)